BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

VM202 trial completes patient administration

June 13, 2013 | News | By BioSpectrum Bureau



Singapore: ViroMed, a leading biotechnology company, announced the final enrollment and administration of 105 patients for the company's ongoing phase II clinical trial of VM202-DPN in US/Korea for the treatment of diabetic peripheral neuropathy. ViroMed expects to confirm results of VM202-DPN phase II clinical trial by second quarter of 2014.

The clinical trial is being held in total of 17 hospitals and has administered VM202 to 105 enrolled patients in both US and Korea. Dr John Kessler, of Northwestern Medical School, Chicago, is leading this investigation. The structure of the study is a double-blind, randomized, placebo-controlled, multicenter study with 20 percent of the enrolled subjects receiving placebo to confirm the efficacy of the drug.

This clinical study was supported by the Korean Ministry of Health and Welfare for 'Health Care Research and Development Project' as a national project under the title "US Phase II Clinical Study of Diabetic Peripheral Neuropathy drug (VM202-DPN)."